| Literature DB >> 33933633 |
Ana Caroline Melo Dos Santos1, Bárbara Rayssa Correia Dos Santos1, Bruna Brandão Dos Santos1, Edilson Leite de Moura1, Jean Moisés Ferreira2, Luana Karen Correia Dos Santos1, Susana Paiva Oliveira1, Renise Bastos Farias Dias1, Aline Cristine Pereira E Silva2, Karol Fireman de Farias2, Elaine Virgínia Martins de Souza Figueiredo3.
Abstract
The Severe acute respiratory syndrome may be caused by coronavirus disease which has resulted in a global pandemic. Polymorphisms in the population play a role in susceptibility to severity. We aimed to perform a systematic review related to the effect of single nucleotide polymorphisms in the development of severe acute respiratory syndrome (SARS). Twenty-eight eligible articles published were identified in PubMed, ScienceDirect, Web of Science, PMC Central and Portal BVS and additional records, with 20 studies performed in China. Information on study characteristics, genetic polymorphisms, and comorbidities was extracted. Study quality was assessed by the STrengthening the REporting of Genetic Association (STREGA) guideline. Few studies investigated the presence of polymorphisms in HLA, ACE1, OAS-1, MxA, PKR, MBL, E-CR1, FcγRIIA, MBL2, L-SIGN (CLEC4M), IFNG, CD14, ICAM3, RANTES, IL-12 RB1, TNFA, CXCL10/IP-10, CD209 (DC-SIGN), AHSG, CYP4F3 and CCL2 with the susceptibility or protection to SARS-Cov. This review provides comprehensive evidence of the association between genetic polymorphisms and susceptibility or protection to severity SARS-CoV. The literature about coronavirus infection, susceptibility to severe acute respiratory syndrome (SARS) and genetic variations is scarce. Further studies are necessary to provide more concrete evidence, mainly related to Covid-19.Entities:
Keywords: Coronavirus; Genetic polymorphism; Severe acute respiratory syndrome; Susceptibility
Year: 2021 PMID: 33933633 PMCID: PMC8084602 DOI: 10.1016/j.meegid.2021.104846
Source DB: PubMed Journal: Infect Genet Evol ISSN: 1567-1348 Impact factor: 3.342
Fig. 1Flow diagram Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) illustrating the studies' selection process.
Characteristics of studies included in this review.
| Author, year | Country | Design | Sample size | Genotyping method | Gene | SNPs | Outcomes | HWE (Y/N) | STREGA total score | |
|---|---|---|---|---|---|---|---|---|---|---|
| Case | Control | |||||||||
| Taiwan | Case–control | 37 | 190 | PCR-SSOP | HLA-class I and II | HLA-A, B and DRB | HLA-B*4601 and risk to SARS | NR | 15 | |
| Vietnam | Case–control | 44 | 153 | Conventional PCR | ACE1 | insertion/deletion (I/D) | progression of pneumonia (D allele) | NR | 15 | |
| China | Case–control | 168 | 328 | Real-Time PCR | ACE2 | rs2285666, rs4646142, rs714205, rs2106809 and rs2074192 | No relation | Y | 18 | |
| China | Case–control | 140 | 326 | Conventional PCR | ACE | insertion/deletion (I/D) | No relation | Y | 18 | |
| Vietnam | Case-control | 44 | 103 | PCR - RFLP | associated with SARS-CoV infection or development of SARS | N | 19 | |||
| PCR - RFLP | N | |||||||||
| PCR - RFLP | N | |||||||||
| China | Case- control | 569 | 1189 | Real- time -PCR | susceptibility to SARS | NR | 20 | |||
| Vietnam | Case- control | 44 | 103 | PCR - RFLP | ACE2 | rs2285666, rs4646140, rs25082, rs25424, rs4646165, rs2301693, rs2301692, rs30816, rs4646174, rs33121, rs33205, rs36655, rs38926, rs39663, rs39705 and rs39844 | No relation | NR | 18 | |
| China | Case–control | 54 | 212 | PCR - RFLP | E-CR1 | CR1 Hind III | Progression of SARS | Y | 18 | |
| China | Case-control | 180 | 200 | PCR- SSP | FcγRIIA | R-H-131 | Susceptibility to SARS | NR | 18 | |
| MBL2 | rs11003125, rs7096206, rs5030737, rs1800450 and rs1800451 | Susceptibility to SARS | NR | |||||||
| China | Case–control | 352 | 392 | Conventional PCR | MBL | -596, -550, -435, -427, -349, -336, -329 to >324, -221, -70, 4, 223, 230, 239 and 366 | B allele had an increased susceptibility to SARS-CoV infection | Y | 18 | |
| China | Case-control | 285 | 380 | Conventional PCR | L-SIGN (CLEC4M) | CLEC4M 69-nucleotide tandem repeats in exon 4 | homozygosity for L-SIGN and protective role | N | 15 | |
| China | Case-control | 66 | 64 | Conventional PCR | OAS1 | 3′UTR 347 locus of the exon 8 | susceptibility to SARS | NR | 15 | |
| PCR - RFLP | MxA | - 88 | susceptibility to SARS | NR | ||||||
| China | Case-control | 476 | 449 | RT-PCR | Y | 15 | ||||
| No relation | Y | |||||||||
| No relation | Y | |||||||||
| China | Case-control | 152 | 198 | PCR - RFLP | CD14 | s2569190-159 | Genotype CC and risk | NR | 14 | |
| TLR2 | 2180 and 2408 | No relation | NR | |||||||
| TLR4 | 12,874 and 13,174 | No relation | NR | |||||||
| China | Case-control | 817 | 906 | Real-Time PCR | ICAM3 | rs2304237 (Asp143Gly) | Susceptibility of SARS | Y | 15 | |
| Conventional PCR | FCER2 | rs4804773 (Trp62Arg); rs889182; rs1990975; rs2287868 and rs2303112. | No relation | Y | ||||||
| China | Case-control | 495 | 578 | PCR | RANTES -28 G allele was associated with SARS susceptibility in Hong Kong Chinese | Y | 18 | |||
| Khoo et al., 2008 | China | Case-control | 285 | 380 | PCR Multiplex | Not described | No relation | NR | 18 | |
| China | Case- control | 115 | 296 | PCR- RFLP | + 705, + 1158, + 1196 and + 1664 | (CT e TT) increased risk of developing SARS | N | 20 | ||
| China | Case-control | 75 | 92 | PCR- SBT | CT genotype protective effect and TT genotype, CT and CC were found associated with a risk effect | NR | 16 | |||
| Xiong et al., 2008 | China | Case- control | 95 | 403 | PCR- SSP | HLA | HLA-A, HLA-B, HLA-DRB1 | No relation | N | 18 |
| Vietnam | Case-control | 62 | 50 | PCR | HLA classe I and class II | exons 2 and 3 of HLA -A, -B, and -C | HLA-DRB1*1202 with susceptibility to SARS | Y | 15 | |
| exon 2 of HLA-DRB1 and -DQB1 | ||||||||||
| Wang et al., 2009 | China | Case-control | 376 | 523 | PCR | MASP2 | rs12711521, rs2261695, rs2273346 and rs7548659 | No relation | NR | 15 |
| China | Case-control | 824 | 471 | Real-Time PCR | CD209 (DC-SIGN) | −336A (rs4804803) | No relation | Y | 18 | |
| CXCL10/IP-10 | −938 | Protective | NR | 15 | ||||||
| HO-1 | −497 | No relation | NR | |||||||
| Fgl2 | +158 (rs2075761) | +158 T/* and Risk | NR | |||||||
| China | Cohort | 824 | – | Real-Time PCR | CD209 (DC-SIGN) | −336A (rs4804803) | higher standardized LDH levels | Y | 15 | |
| Ching et al., 2010 | China | Case-control | 792 | 418 | PCR | -88 T-positive and -123A-positive genotypes were significantly associated with decreased susceptibility to SARS coronavirus infection | Y | 16 | ||
| China | Case-control | 624 | 791 | PCR-RFLP | AHSG | rs2248690, rs2077119, rs4917, rs2593813 and rs4918 | rs2248690 | Y | 16 | |
| CYP4F3 | rs3794987, rs1159776, rs4646519 and rs1290625 | rs3794987 GG/AG and increased susceptibility to SARS | Y | |||||||
| China | Case-control | 932 | 982 | PCR-RFLP | CCL2 | rs1024611 | risk of SARS-CoV infection | Y | 16 | |
| MBL | Codon 54 variant (A > B) | risk of SARS-CoV infection | Y | |||||||
| rs1800450 | ||||||||||
| Italian and Spanish | Case–control | 1760 | 2205 | Global Screening Array (GSA) | 3p21.31 | rs11385942 (SLC6A20, LZTFL1, CCR9, FYCO1, CXCR6 and XCR1) | association signal | NR | 20 | |
| 9q34.2 | rs657152 (ABO blood group locus) | higher risk in blood group A to SARS-Cov-2 | NR | |||||||
The quality of reporting using the STrengthening the REporting of Genetic Association (STREGA) guideline.
| Author, year | Description of genotyping methods and errors | Description of modeling population stratification | Description of modeling haplotype Variation | Statement of Whether Hardy-Weinberg Equilibrium was considered | Statement of whether the study is the first report of a genetic association, a replication effort, or both | Total score | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Genotyping methods and platforms | Error rates and call rates | Laboratory/center where the genotyping was done | Conducting genotypes simultaneously or in smaller batches | The numbers of individuals for whom genotyping was attempted and successful | ||||||
| Y | N | N | N | Y | Y | N | N | N | 3 | |
| Y | N | N | N | Y | Y | N | N | N | 3 | |
| Y | N | N | N | Y | Y | N | Y | N | 4 | |
| Y | N | N | N | Y | Y | N | Y | N | 4 | |
| Y | N | N | Y | N | Y | Y | Y | N | 5 | |
| Y | N | Y | Y | N | Y | Y | Y | N | 6 | |
| Y | N | N | Y | Y | Y | N | N | N | 4 | |
| Y | N | N | N | Y | Y | N | Y | N | 4 | |
| Y | Y | N | Y | N | N | Y | N | N | 4 | |
| Y | N | N | N | Y | Y | N | Y | N | 4 | |
| Y | N | N | N | N | Y | N | Y | N | 3 | |
| Y | N | N | N | Y | Y | N | N | N | 3 | |
| Y | N | N | Y | N | N | N | Y | N | 3 | |
| Y | N | N | N | Y | M | N | N | N | 2 | |
| Y | N | N | N | Y | Y | N | Y | N | 4 | |
| Y | Y | N | Y | N | Y | Y | Y | N | 6 | |
| Y | N | N | Y | Y | N | N | Y | N | 4 | |
| Y | Y | N | Y | Y | Y | Y | Y | N | 7 | |
| Y | N | N | Y | N | Y | N | Y | N | 4 | |
| Y | N | N | Y | Y | Y | Y | N | N | 5 | |
| Y | N | N | N | Y | M | N | Y | N | 3 | |
| Y | N | N | Y | N | N | N | Y | N | 3 | |
| Y | N | N | N | Y | Y | N | Y | N | 4 | |
| Y | N | N | N | N | Y | N | Y | N | 3 | |
| Y | Y | N | Y | N | Y | Y | Y | N | 6 | |
| Y | N | N | N | Y | Y | N | Y | N | 4 | |
| Y | N | N | N | Y | Y | N | Y | N | 4 | |
| Y | N | Y | Y | Y | Y | N | Y | Y | 7 | |